Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Loading...
Community
/
United States
/
Pharmaceuticals & Biotech
/
Puma Biotechnology
PBYI
Puma Biotechnology
Single-Asset Reliance Will Deepen Revenue Erosion
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 2 Analysts
Published
01 Jun 25
Updated
20 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$2.00
159.0% overvalued
intrinsic discount
20 Aug
US$5.18
1Y
103.9%
7D
1.8%
Loading
1Y
103.9%
7D
1.8%
Author's Valuation
US$2.0
159.0% overvalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$2.0
159.0% overvalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-301m
280m
2014
2017
2020
2023
2025
2026
2028
Revenue US$213.7m
Earnings US$14.4m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
-1.79%
Biotech revenue growth rate
11.84%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.96%
Calculation
US$14.37m
Earnings '28
x
9.19x
PE Ratio '28
=
US$132.11m
Market Cap '28
US$132.11m
Market Cap '28
/
54.42m
No. shares '28
=
US$2.43
Share Price '28
US$2.43
Share Price '28
Discounted to 2025 @ 6.95% p.a.
=
US$1.98
Fair Value '25
